PT1068870E - Agentes antitumorais - Google Patents
Agentes antitumoraisInfo
- Publication number
- PT1068870E PT1068870E PT99910779T PT99910779T PT1068870E PT 1068870 E PT1068870 E PT 1068870E PT 99910779 T PT99910779 T PT 99910779T PT 99910779 T PT99910779 T PT 99910779T PT 1068870 E PT1068870 E PT 1068870E
- Authority
- PT
- Portugal
- Prior art keywords
- active ingredients
- antitumor
- stilbene derivative
- antitumor activity
- antitumor agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10870898 | 1998-04-03 | ||
JP22984398 | 1998-08-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1068870E true PT1068870E (pt) | 2006-10-31 |
Family
ID=26448545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99910779T PT1068870E (pt) | 1998-04-03 | 1999-03-29 | Agentes antitumorais |
Country Status (19)
Country | Link |
---|---|
US (6) | US6462087B1 (pt) |
EP (1) | EP1068870B1 (pt) |
JP (3) | JP4470321B2 (pt) |
KR (1) | KR100598474B1 (pt) |
CN (1) | CN1140272C (pt) |
AT (1) | ATE328599T1 (pt) |
AU (1) | AU747599C (pt) |
BR (1) | BR9909393A (pt) |
CA (1) | CA2326761C (pt) |
DE (1) | DE69931766T2 (pt) |
DK (1) | DK1068870T3 (pt) |
ES (1) | ES2267255T3 (pt) |
HU (1) | HUP0102521A3 (pt) |
IL (1) | IL138723A (pt) |
NO (1) | NO328704B1 (pt) |
NZ (1) | NZ507221A (pt) |
PT (1) | PT1068870E (pt) |
RU (1) | RU2215525C2 (pt) |
WO (1) | WO1999051246A1 (pt) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
PT1068870E (pt) * | 1998-04-03 | 2006-10-31 | Ajinomoto Kk | Agentes antitumorais |
US7037906B1 (en) * | 2000-12-22 | 2006-05-02 | Oxigene, Inc. | Methods for modulating tumor growth and metastasis |
US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
CA2433417C (en) * | 2001-01-18 | 2010-10-19 | Welichem Biotech Inc. | Novel 1,2-diphenylethene derivatives for treatment of immune diseases |
US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
DK1407784T3 (da) * | 2001-06-25 | 2011-02-28 | Ajinomoto Kk | Antitumormidler |
KR20030018800A (ko) * | 2001-08-31 | 2003-03-06 | 주식회사 프로메디텍 | 시토크롬 피450 1비1 억제활성을 갖는 페닐환 유도체 및약학적으로 허용가능한 그의 염, 그의 제조방법 및 이를함유하는 조성물 |
US7371773B2 (en) * | 2003-02-04 | 2008-05-13 | Kabushiki Kaisha Yakult Honsha | Breast cancer resistance protein (BCRP) inhibitor |
DK2368553T3 (en) * | 2003-04-08 | 2015-02-09 | Progenics Pharm Inc | Pharmaceutical preparation comprising methylnaltrexone |
AU2006214164B2 (en) * | 2005-02-17 | 2010-12-09 | Synta Pharmaceuticals Corp. | Isoxazole combretastin derivatives for the treatment of disorders |
US9662390B2 (en) * | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8524731B2 (en) * | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
FR2895258B1 (fr) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
CA2682129A1 (en) | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms and uses thereof |
WO2008121348A2 (en) * | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
ES2493590T3 (es) | 2007-03-29 | 2014-09-12 | Wyeth Llc | Antagonistas de receptores opioides periféricos y usos de los mismos |
US8095816B1 (en) | 2007-04-05 | 2012-01-10 | Marvell International Ltd. | Processor management using a buffer |
US8443187B1 (en) | 2007-04-12 | 2013-05-14 | Marvell International Ltd. | Authentication of computing devices in server based on mapping between port identifier and MAC address that allows actions-per-group instead of just actions-per-single device |
US8321706B2 (en) | 2007-07-23 | 2012-11-27 | Marvell World Trade Ltd. | USB self-idling techniques |
DK2219451T3 (en) | 2007-11-21 | 2015-01-12 | Oxigene Inc | A method for the treatment of hematopoietic neoplasms |
CA2713568C (en) | 2008-02-06 | 2016-09-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
EP2278966B1 (en) * | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
CA2676881C (en) * | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
BRPI0921249A8 (pt) | 2008-11-14 | 2018-12-04 | Histogen Inc | uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterápico na preparação de uma composição, e composições para o tratamento do cãncer |
FR2945210B1 (fr) * | 2009-05-07 | 2011-07-01 | Sanofi Aventis | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |
FR2953518B1 (fr) | 2009-12-03 | 2012-01-20 | Sanofi Aventis | Procede de preparation d'un derive de combretastatine |
EP2397135A1 (en) | 2010-06-18 | 2011-12-21 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
EP2481404A1 (en) | 2010-11-15 | 2012-08-01 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
KR20130088753A (ko) | 2010-06-18 | 2013-08-08 | 사노피 | 옴브라불린, 탁산 유도체 및 백금 유도체를 포함하는 항종양 조합물 |
EP2407161A1 (en) | 2010-07-13 | 2012-01-18 | Sanofi | An antitumoral combination comprising ombrabulin and bevacizumab |
FR2968557A1 (fr) | 2010-12-09 | 2012-06-15 | Sanofi Aventis | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab |
JP2014512337A (ja) | 2011-01-28 | 2014-05-22 | ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | スチルベン類似体およびがんを処置する方法 |
AU2012275841A1 (en) | 2011-06-27 | 2014-01-16 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
US9141394B2 (en) | 2011-07-29 | 2015-09-22 | Marvell World Trade Ltd. | Switching between processor cache and random-access memory |
FR2978662A1 (fr) * | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie |
FR2978663A1 (fr) | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie |
US9436629B2 (en) | 2011-11-15 | 2016-09-06 | Marvell World Trade Ltd. | Dynamic boot image streaming |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
US9575768B1 (en) | 2013-01-08 | 2017-02-21 | Marvell International Ltd. | Loading boot code from multiple memories |
US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
US9458086B1 (en) | 2013-07-03 | 2016-10-04 | University Of South Florida (A Florida Non-Profit Corporation) | Compositions and methods for adipocyte modulation |
US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
CN107311846B (zh) * | 2017-07-25 | 2022-05-13 | 上海华理生物医药股份有限公司 | 偕二氟乙基取代的二苯乙烯和二苯乙烷类衍生物及其制备方法和应用 |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH588505A5 (pt) * | 1972-06-08 | 1977-06-15 | Research Corp | |
JPS56103192A (en) * | 1980-01-18 | 1981-08-18 | Yoshinori Kitani | Novel platinum complex |
US4935450A (en) * | 1982-09-17 | 1990-06-19 | Therapeutical Systems Corporation | Cancer therapy system for effecting oncolysis of malignant neoplasms |
CA1338645C (en) * | 1987-01-06 | 1996-10-15 | George R. Pettit | Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins" |
CA1340994C (en) | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
US5561136A (en) * | 1990-12-13 | 1996-10-01 | Merrell Pharmaceuticals Inc. | Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent |
GB9106177D0 (en) * | 1991-03-22 | 1991-05-08 | Aston Molecules Ltd | Substituted diphenylethylenes and analogues or derivatives thereof |
US5525622A (en) * | 1991-08-28 | 1996-06-11 | Bayer Aktiengesellschaft | Substituted pyrazolines |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5844001A (en) * | 1993-02-26 | 1998-12-01 | Research Development Foundation | Combination platinum chemotherapeutic/antiestrogen therapy for human cancers |
US5409690A (en) * | 1993-06-23 | 1995-04-25 | Chemex Pharmaceuticals, Inc. | Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol |
US5731353A (en) * | 1993-09-08 | 1998-03-24 | Ajinomoto Co., Inc. | Stilbene derivatives and pharmaceutical compositions containing them |
TW325458B (en) | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
JP3163391B2 (ja) | 1995-03-07 | 2001-05-08 | 味の素株式会社 | スチルベン誘導体及びそれを含有する制癌剤 |
TW334418B (en) * | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
US5700826A (en) * | 1995-06-07 | 1997-12-23 | Ontogen Corporation | 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance |
AU6906396A (en) * | 1995-08-30 | 1997-03-19 | Arch Development Corporation | Methods and compositions including dna damaging agents and tyrosine kinase inhibitors or activators |
WO1998033481A1 (en) | 1997-02-05 | 1998-08-06 | Pharmacia & Upjohn Company | Lipid complexes and liposomes of highly insoluble platinum complexes |
PT1068870E (pt) * | 1998-04-03 | 2006-10-31 | Ajinomoto Kk | Agentes antitumorais |
CZ292170B6 (cs) | 1998-08-14 | 2003-08-13 | Pliva-Lachema A.S. | Farmaceutická kompozice s protinádorovým účinkem na bázi carboplatiny |
GB9903403D0 (en) * | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Substituted stilbene compounds with vascular damaging activity |
GB9918912D0 (en) * | 1999-08-12 | 1999-10-13 | Angiogene Pharm Ltd | New stilbenes with vascular damaging activity |
EP1351573A4 (en) * | 2000-12-22 | 2007-03-28 | Bristol Myers Squibb Co | METHOD FOR MODULATING TUMOR WATCHTOWER AND METASTASIS |
US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
DK1407784T3 (da) * | 2001-06-25 | 2011-02-28 | Ajinomoto Kk | Antitumormidler |
-
1999
- 1999-03-29 PT PT99910779T patent/PT1068870E/pt unknown
- 1999-03-29 DE DE69931766T patent/DE69931766T2/de not_active Expired - Lifetime
- 1999-03-29 ES ES99910779T patent/ES2267255T3/es not_active Expired - Lifetime
- 1999-03-29 AU AU29607/99A patent/AU747599C/en not_active Ceased
- 1999-03-29 AT AT99910779T patent/ATE328599T1/de active
- 1999-03-29 CA CA002326761A patent/CA2326761C/en not_active Expired - Fee Related
- 1999-03-29 KR KR1020007010971A patent/KR100598474B1/ko not_active IP Right Cessation
- 1999-03-29 JP JP2000542017A patent/JP4470321B2/ja not_active Expired - Fee Related
- 1999-03-29 WO PCT/JP1999/001633 patent/WO1999051246A1/ja active IP Right Grant
- 1999-03-29 BR BR9909393-6A patent/BR9909393A/pt not_active Application Discontinuation
- 1999-03-29 DK DK99910779T patent/DK1068870T3/da active
- 1999-03-29 RU RU2000127751/14A patent/RU2215525C2/ru not_active IP Right Cessation
- 1999-03-29 CN CNB998067555A patent/CN1140272C/zh not_active Expired - Fee Related
- 1999-03-29 HU HU0102521A patent/HUP0102521A3/hu unknown
- 1999-03-29 EP EP99910779A patent/EP1068870B1/en not_active Expired - Lifetime
- 1999-03-29 NZ NZ507221A patent/NZ507221A/xx not_active IP Right Cessation
- 1999-03-29 IL IL13872399A patent/IL138723A/xx not_active IP Right Cessation
-
2000
- 2000-09-29 NO NO20004911A patent/NO328704B1/no not_active IP Right Cessation
- 2000-10-03 US US09/678,406 patent/US6462087B1/en not_active Expired - Lifetime
-
2002
- 2002-05-29 US US10/156,105 patent/US20020193434A1/en not_active Abandoned
- 2002-06-12 US US10/166,763 patent/US6992106B2/en not_active Expired - Fee Related
-
2005
- 2005-08-04 US US11/196,454 patent/US7655696B2/en not_active Expired - Fee Related
-
2008
- 2008-12-15 US US12/334,846 patent/US7973076B2/en not_active Expired - Fee Related
-
2009
- 2009-08-24 JP JP2009192918A patent/JP5056816B2/ja not_active Expired - Fee Related
- 2009-11-20 US US12/622,508 patent/US20100069486A1/en not_active Abandoned
- 2009-12-10 JP JP2009280444A patent/JP5120368B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1068870T3 (da) | Antitumormidler | |
BR0308854A (pt) | Benzazolas substituìdas e seus usos como inibidoras de quinase raf | |
ATE386808T1 (de) | Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel | |
DE69535805D1 (de) | Neue Carbamate- und Harnstoffderivate als Mittel gegen Multidrugresistenz | |
CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
EA200200616A1 (ru) | Химические производные и их применение в качестве антителомеразного агента | |
BR9814923A (pt) | Método para tratamento de doença de alzheimer | |
BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
ES2192832T3 (es) | Uso de compuestos macrolidos para tratar glaucoma. | |
DE60108489D1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
DE69835824D1 (de) | Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin | |
MXPA04001256A (es) | Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso. | |
IT1264530B (it) | Impiego dei polisaccaridi nelle neuropatie atrofico degenerative | |
ATE530184T1 (de) | Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe | |
ATE516027T1 (de) | Orazamid orotat zur vorbeugung von leberschäden | |
MXPA03011270A (es) | Uso de antagonistas rank para tratar cancer. | |
MXPA04001328A (es) | Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso. | |
IT1304183B1 (it) | Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici. | |
DE69113162T2 (de) | Antiallergische Mischung. | |
HK1074840A1 (en) | Novel dithiolopyrrolones with therapeutic activity | |
WO2002076393A3 (en) | Antiagionecic, antitumor, chemopreventative agents | |
PT862433E (pt) | Composicao farmaceutica espumante topica para o tratamento de dermatoses induzidas por pityrosporum oval | |
DE60203895D1 (de) | Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie | |
ATE346080T1 (de) | Steroid-verbindungen mit anti-tumoraler wirkung | |
NZ331374A (en) | Phenanthridine compounds and pharmaceutical compositions thereof |